Literature DB >> 28301912

Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience.

Halil Atas1, Ahmet Anıl Sahin1, Dilek Barutçu Atas2, Murat Sunbul1, Alper Kepez1, Mehmet Agirbasli3.   

Abstract

Time in therapeutic range (TTR) of international normalized ratio is crucial for the safety and efficacy of anticoagulation with warfarin and it is influenced by many factors. There are limited data about the quality of warfarin therapy and its effects on clinical outcomes in Turkey. The aim of this study is to demonstrate the quality of anticoagulant therapy with warfarin and evaluate the parameters that affect the quality of warfarin therapy. A total of 170 patients with atrial fibrillation (AF; mean age: 62.2 ± 13.3; 69.2% female) treated with warfarin were included in this study. The mean follow-up period was 20 ± 8.4 months. The mean TTR levels of all patients were found to be 54.2% ± 21.4%. The TTR levels were similar in patients with valvular AF (VAF) and nonvalvular AF (NVAF). Logistic regression analysis revealed that elderly, heart failure (HF), and renal dysfunction were independent predictors of lower TTR. There were no significant differences between the VAF and NVAF subgroups regarding the incidence of mortality, stroke, and myocardial infarction. Cox regression analysis revealed that HF, coronary artery disease, and renal dysfunction were independent predictors of clinical outcomes in addition to lower TTR. Our results provide data regarding the quality of anticoagulation with warfarin from a single tertiary center in Istanbul, Turkey. The questions remain in seeking quality improvement in anticoagulation.

Entities:  

Keywords:  heart failure; time in therapeutic range; warfarin

Mesh:

Substances:

Year:  2017        PMID: 28301912      PMCID: PMC6714662          DOI: 10.1177/1076029617695484

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  31 in total

1.  Pilot study for evidence-based nursing management: improving the levels of job satisfaction, organizational commitment, and intent to leave among nurses in Turkey.

Authors:  Havva Arslan Yurumezoglu; Gulseren Kocaman
Journal:  Nurs Health Sci       Date:  2012-03-28       Impact factor: 1.857

2.  Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.

Authors:  Shimoli V Shah; Brian F Gage
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

3.  Quality of anticoagulation control among patients with atrial fibrillation.

Authors:  Osnat C Melamed; Gilad Horowitz; Asher Elhayany; Shlomo Vinker
Journal:  Am J Manag Care       Date:  2011-03       Impact factor: 2.229

4.  Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

Authors:  Harvey D White; Michael Gruber; Jan Feyzi; Scott Kaatz; Hung-Fat Tse; Steen Husted; Gregory W Albers
Journal:  Arch Intern Med       Date:  2007-02-12

5.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

6.  Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.

Authors:  Seol Young Han; Sebastian T Palmeri; Samuel H Broderick; Vic Hasselblad; Dave Rendall; Scott Stevens; Alan Tenaglia; Eric Velazquez; David Whellan; Galen Wagner; John F Heitner
Journal:  J Electrocardiol       Date:  2012-10-11       Impact factor: 1.438

7.  The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER).

Authors:  Faruk Ertas; Nihan Kahya Eren; Hasan Kaya; Alpay Aribas; Goksel Acar; Mehmet Kanadasi; Selcuk Gedik; Mustafa Oylumlu; Murat Yuksel; Mehmet Siddik Ulgen
Journal:  Cardiol J       Date:  2013-05-15       Impact factor: 2.737

8.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.

Authors:  William L Baker; Deborah A Cios; Stephen D Sander; Craig I Coleman
Journal:  J Manag Care Pharm       Date:  2009-04

10.  Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence.

Authors:  Adam J Rose; Donald R Miller; Al Ozonoff; Dan R Berlowitz; Arlene S Ash; Shibei Zhao; Joel I Reisman; Elaine M Hylek
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.